Table 1.
Analyte | Placebo Treatment Phase | Omeprazole Treatment Phase | Mean Difference (95% CI) | RR | P‐value |
---|---|---|---|---|---|
Serum | |||||
Total calcium (mg/dL) | |||||
Day 0 | 10.2 ± 0.2 | 10.3 ± 0.6 | 9.5–11.2 mg/dL | 0.10 | |
Day 30 | 10.6 ± 0.3 | 10.8 ± 0.1 | −0.2 (95% CI of mean diff: −0.4–0.1) | ||
Day 60 | 10.4 ± 0.5 | 10.5 ± 0.3 | |||
Ionized calcium (mmol/L) | |||||
Day 0 | 1.35 (1.27–1.40) * | 1.35 (1.25–1.39) * | — | — | — |
Day 30 | 1.37 (1.33–1.43) * | 1.39 (1.31–1.45) * | — | ||
Day 60 | 1.29 (1.18–1.30) * | 1.29 (1.25–1.31) * | — | ||
Total magnesium (mmol/L) | |||||
Day 0 | 0.87 ± 0.05 | 0.88 ± 0.04 | 0.7–1.0 mmol/L | 0.29 | |
Day 30 | 0.81 ± 0.04 | 0.91 ± 0.08 | −0.02 (95% CI of mean diff: −0.06–0.02) | ||
Day 60 | 0.91 ± 0.04 | 0.85 ± 0.06 | |||
Ionized magnesium (mmol/L) | |||||
Day 0 | 0.58 ± 0.02 | 0.56 ± 0.04 | — | 0.27 | |
Day 30 | 0.57 ± 0.04 | 0.58 ± 0.06 | −0.01 (95% CI of mean diff: −0.04–0.01) | ||
Day 60 | 0.53 ± 0.03 | 0.57 ± 0.01 | |||
Sodium (mEq/L) | |||||
Day 0 | 151 ± 1 | 152 ± 1 | 148–155 mEq/L | — | |
Day 30 | 153 ± 3 | 154 ± 2 | 1 (95% CI of mean diff: ‐1 – 3) | ||
Day 60 | 150 ± 1 | 151 ± 1 | |||
Potassium (mEq/L) | |||||
Day 0 | 3.6 ± 0 | 4.2 ± 0.4 | 2.8–4.8 mEq/L | — | |
Day 30 | 3.9 ± 0.3 | 4.1 ± 0.4 | −0.3 (95% CI of mean diff: −0.6–0) | ||
Day 60 | 3.7 ± 0.3 | 3.8 ± 0.2 | |||
Chloride (mEq/L) | |||||
Day 0 | 115 ± 2 | 119 ± 2 | 113–123 mEq/L | — | |
Day 30 | 117 ± 3 | 118 ± 2 | −2 (95% CI for mean diff: −4–0) | ||
Day 60 | 116 ± 2 | 117 ± 2 | |||
Blood | |||||
Platelets (×103/uL) | |||||
Day 0 | 365 ± 81 | 250 ± 22 | — | — | |
Day 30 | 277 ± 109 | 256 ± 121 | 38 (95% CI for mean diff: −37–113) | ||
Day 60 | 246 ± 65 | 269 ± 70 | |||
Heinz bodies (%) | |||||
Day 0 | 0.1 (0–0.2) * | 0.1 (0–0.3) * | — | — | — |
Day 30 | 0.05 (0–0.2) * | 0.2 (0–0.4) * | — | ||
Day 60 | 0.0 (0–0.1) * | 0.15 (0–0.4) * | — |